Elizabeth Phillips, MD

 

Academic Rank:

Professor of Medicine

Title:

Physician Scientist

 

Director of Personalized Immunology, Oates Institute for Experimental Therapeutics

Joined Vanderbilt:

2013

 

Office Address

1161 21st Avenue South

Nashville, TN 37232-2582

Phone: (615) 322-2035

Fax: (615) 343-6160

Webpage: https://medicine.mc.vanderbilt.edu/id

 

 

Education & Training

Undergraduate

University of Alberta, 1987

Medical

University of Alberta 1989

Internship

University of Ottawa- Ottawa General Hospital 1989-1990

Residency

University of Toronto- St. Michael’s Hospital, The Toronto Hospital 1990-1993

Fellowship

University of Toronto 1993-1999

                                               

Honors/Awards

Research Presentation Award Division of Infectious Diseases, University of Toronto 1997

Bill Mahon Research Presentation Award, Division of Clinical Pharmacology, University of Toronto1998

Research Fellowship Award, Canadian Society for Clinical Pharmacology 1998-1999

Young Investigator’s Award, Canadian Infectious Diseases Society 2000

Piafsky Young Investigator Award, Canadian Society for Clinical Pharmacology 2004

Career Support Award, AIDS Bureau, Ontario Ministry of Health (Canada) 2000-2001

Career Support Award, Ontario HIV Treatment Network 2001-2006

 

Research Keywords

HIV, drug safety, pharmacology, personalized medicine, drug hypersensitivity, HLA, immunopathogenesis, severe H1N109 disease

 

Selected Publications

Hertz T, Oshansky C, Roddam P, DeVincenzo J, Caniza M, Jojic N, Mallal S, Phillips E, James I, Halloran E, Thomas P, Corey L.  HLA targeting efficiency correlates with human T-cell response magnitude and mortality from influenza A infection. Proc Nat Acad Sci 2013 (in press).

Phillips E, Mallal S. HLA-B*5701 and flucloxacillin associated liver disease. AIDS 2013;27(3):491-2.

Phillips E, Bartlett J, Sanne I, Lederman M, Hinkle J, Rousseau F, Dunn D, Pavlos R James I, Mallal S, Haas D. Association between HLA-DRB1*0102, HLA-B*58:01 and hepatotoxicity during initiation of nevirapine containing regimens in South Africa.  JAIDS 2013;62(2):e55-57.

Mcgettigan BD, Hew M, Phillips E, McLean-Tooke A.  Sulphadiazine-induced renal stones in a 63 year old HIVinfected man treated for toxoplasmosis.  BMJ Case Reports 2012;doi:10:1136/bcr-2012-0066378.  Published online 21 September 2012.

Ostrov D, Grant B, Pompeu Y, Sidney J, Harndahl M, Southwood S, Oseroff C, Lu S, Jakoncic J, de Oliveira C, Yang L, Mei H, Leming S, Shabanowitz J, English M, Wriston A, Lucas A, Phillips E, Mallal S, Grey H, Sett A, Hunt D, Buus S, Peters B.  Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire.  Proc Nat Acad Sci 2012; early edition Epub 29 May 2012; 109(25):9959-64.

Hammond E, McKinnon E, Glendenning P, Williams R, Mallal S, Phillips E. Association between 25-OH vitamin D and insulin is independent of lipoatrophy in HIV.  Clin endocrinol 2012;76:201-6.

Kuritzkes D, Ritchie M, Amur S, Gage B, Maartens G, Masys D, Fellay J, Phillips E, Ribaudo H, Freedberg K, Petropoulos C, Manolio T, Gulick R, Haubrich R, Kim P, Dehlinger M, Abebe R, Teleni A.  Pharmacogenomics of HIV Therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases.  HIV Clin Trials 2011;12(5);277-85.

Lee MH, Stocker S, Anderson A, Phillips E, Nolan D, Williams K, Graham G, Sullivan J, Day R.  Initiating allopurinol therapy: do we need to know the patient’s HLA status?  Internal Med J. 2011 Jul 25.

Phillips E, Mallal S.  HLA-B*1502 screening and toxic effects of carbamazepine. New Eng J Med 2011;365(7):672.

Pirmohamed M, Friedmann PS, Molokhia M, Loke Y, Smith C, Phillips E, Grenade L, Carleton B, Amati-Papaluca M, Demoly P, Shear NH.  Phenotype standardization for immune-mediated drug-induced skin injury.  Clin Pharm Ther 2011;89(6):896-901.

Phillips E, Chung WH, Mockenhaupt M, Roujeau JC, Mallal S.  Drug hypersensitivity:  Pharmacogenetics and clinical syndromes.  Journal of Allergy and Clin Immunol 2011;127:S60-6.

Hertz T, Nolan D, James I, John M, Gaudieri S, Phillips E, Huang J, Riadi G, Mallal S, Jojic N.  Mapping the landscape of host-pathogen co-evolution.  HLA class I binding  and its relationship with evolutionary conservation in human and viral proteins.  J of Virol 2011; 85:1310-21.

Chaubey SC, Sinha A, Phillips E,  Russell D and Falhammar H.  Transient Cardiac Arrhythmias Related to Lopinavir-Ritonavir In Two Patients with HIV Infection.  Sexual Health 2009;6:254-7.

Antiretroviral Therapy Cohort Collaboration (ART-CC): Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy:  Not all AIDS-Defining Conditions are created equal.  Clin Infect Dis 2009:48 (15 April) HIV/AIDS

Phillips.E, Hayden A, Gutierex G, Jahnke N, Yip B, Lima V, Hogg R, Harrigan R, Montaner J.  Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity. AIDS 2008;22(4):548-9

Phillips E, Nolan D, Mallal S.  Abacavir Hypersensitivity reply to: Vandekerckhove :. Blot S, Vogelaers D and Abel S, Paturel L, Cabie A.  N Engl J Med 2008;358:23:2514-16

Rauch A, Nolan D, Thurnheer C, Fux C, Cavassini M, Chave J, Opravil M, Phillips E, Mallal S, Furrer H.  Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antiviral Therapy 2008;13:1019-28.

Shear N, Milpied B, Bruynzeel D, Phillips E.  A review of drug patch testing and implications for HIV physicians.  AIDS 2008;22:999-1007.

Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jagel-Guedes E, Rugina S, Kozyrev O, Flores Cid J, Hay P, Nolan D, Hughes S, Hughes, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A for the PREDICT-1 Study Team.  HLA-B*5701 screening for abacavir hypersensitivity.  New Engl J Med 2008; 358:568-579.

Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B,Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips, D, Mallal S, Shaefer M for the SHAPE study team.  High sensitivity of HLA-B*5701 in immunologically-confirmed cases of abacavir hypersensitivity in White and Black patients.  Clin Infect Dis 2008;46:1111-1118.

Almeida CA, Martin A, Nolan D, Lucas A, Cameron P, James, I, Phillips E, Mallal S.  Cytokine profiling in abacavir hypersensitivity patients.  Antiviral Therapy 2008;13:281-8

Hammond E, Almeida C, Mamotte C, Nolan D, Phillips E, Schollaardt T, Gill M, Angel J, Neurath D, Li J, Giulivi T, McIntyre C, Koultchitski G, Wong B, Reis M, Rachlis A, Cole D, Chew C, Neifer S, Lalonde R, Roger M, Jeanneau, Mallal S.  External quality assessment of HLA-B*5701 reporting: an international multi-centre survey.  Antiviral Therapy  2007; 12(7):1027-32.

Raboud J, Lesosky M, Sterling S, Phillips E, Walmsley S, Bayoumi A.  An estimate of the proportion of symptoms reported in self-administered questionnaires that are captured as adverse events in an observational database.  HIV Clinical Trials 2007 ;8(5):311-9. 

Mallal S, Phillips EThe introduction of pharmacogenetic screening to HIV clinical practice – potential benefits and challenges.  European Infectious Diseases 2007;13-18.

Phillips EJ, Gutierrez S, Jahnke N, Yip B, Lima VD, Hogg RS, Harrigan PR, Montaner JSG.  Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug naïve HIV-positive patients.  AIDS 2007 ;21:1561- 68

Martin A, Almeida C, Cameron P, Purcell A, Nolan D, James I, McCluskey J, Phillips E, Landay A, Mallal S. Immune responses to abacavir in antigen-presenting cells from hypersensitive patients.  AIDS 2007;21:1233-1244.

Tansey C, Louie M, Loeb M, Gold W, Muller M, deJager J, Cameron J, Tomlinson G, Mazzulli T, Walmsley S, Rachlis A, Mederski B, Silverman M, Shainhouse Z, Ephtimios I, Avendano M, Downey J, Styra R, Yamamura D, Gerson M, Standbrook M, Marras T, Phillips E, Zamel N, Richardson S, Slutsky A, Herridge M.   One-year outcomes and health-care utilization in survivors of severe acute respiratory syndrome (SARS). Arch Intern Med 2007;167:1312-20 6

Chui CK, Brumme ZL, Brumme CJ, Yip B, Phillips EJ, Montaner JS, Harrigan PR.  A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.  Clin Infect Dis 2007;44:1503-8.

Simor AE, Phillips E, McGeer A, Konvalinka A, Loeb M, Devlin HR, Kiss A.  Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus decolonization.  Clin Infect Dis 2007;44(2):178-85.

Tang P, Walsh S, Murray C, Alterman C, Varia M, Broukhanski G, Chedore P, DeKoven J, Assaad D, Gold W, Ghazarian D, Finkelstein M, Pritchard M, Yaffe B, Jamieson F, Henry B, Phillips E.  Outbreak of acupuncture-associated cutaneous Mycobacterium abscessus infections.  Journal of Cut Med and Surg 2006;10(4):166-9.

Martin A, Krueger R, Almeida C, Nolan D, Phillips E, Mallal S.  A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.  Pharmacogenet Genomics. 2006 May;16(5):353-7.

Phillips E.  Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?  Clin Infect Dis 2006:43(1):103-5.

Nolan D, Phillips E, Mallal S.  Efavirenz and CYP2B6 polymorphism: Implications for drug toxicity and resistance.  Clin Infect Dis 2006 Feb 1;42(3):408-10.

Phillips EJ, Knowles SR.  Sulfonamide cross-reactivity:  fact or fiction?  Ann Pharmacother 2005;39(7):1372-3.

Tailor S, Simor A, Cornish W, Phillips E, Knowles S, Rachlis A.  Glucose homeostatasis abnormalities and gatifloxacin.   Clinical Infect Dis 2006;42:895Clin Infect Dis 2005;41:1269-76

Notman MJ, Phillips EJ, Knowles SR, Weber EA, Shear NH.  Clindamycin skin testing has limited diagnostic potential.  Contact dermatitis 2005;53:335-8..

van Heeswijk RP, Cooper CL, Foster BC, Chauhan B, Shirazi F, Seguin I, Phillips EJ, Mills E.   The effect of high-dose vitamin C on hepatic CYP3A4 activity.  Pharmacotherapy 2005;25:1725-8.

Knowles S, Song G, Rahim S, Binkley K, Phillips E, Shear N.  An underrecognized, yet serious adverse drug reaction:  hydrochlorothiazide-induced non-cardiogenic pulmonary edema.  Pharmacotherapy 2005;25:1258-65.

Antoniou T, Tseng A, van Heeswijk R, Walker S, Giguere P, Phillips EJ.  Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/ritonavir combination therapy in antiretroviral experienced patients.  Ther Drug Monit 2005;27:779-781.

Phillips E, Wong G, Kaul R, Shahabi K, Mallal S, Nolan D, Knowles S, Martin A, Shear N.  Clinical and immunogenetic correlates of abacavir hypersensitivity.  AIDS 2005;19:979-81.

Martin A, Nolan D, James I, Cameron P, Keller J, Moore C, Phillips E, Christiansen F, Mallal S.  Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4+ T cell counts.  AIDS 2005;19(1):97-99.

Mills E, Foster B, van Heeswijk R, Phillips E, Wilson K, Leonard B, Kosuge K, Kanfer I.  Impact of African herbal medicines on antiretroviral metabolism.  AIDS 2005;19(1):95-97.

Mills E, Wilson K, Clarke MJ, Foster B, Walker SE, Rachlis B, DeGroot N, Gold W, Phillips E, Myers SP, Gallicano K.  Milk thistle and indinavir: a randomized controlled pharmacokinetics study.  Eur J of Clin Pharm 2005;6(1):1-7.

Mills EJ, Montori VM, Perri D, Phillips E, Koren G.  Natural Health Product – HIV Drug Interactions: a systematic review.  I J STD and AIDS;16(3):181-186, March 2005.

Tailor SAN, Simor AE, Cornish W, Phillips E, Knowles S, Rachlis A.  Author response to Kanji “Quinolone hyperglycemia and hypoglycemia”  Can J Hosp Pharm 2004;57(3):182.  Analysis of spontaneous reports of hypoglycemia and hyperglycemia associated with marketed systemic fluoroquinolones made to the Canadian adverse drug reaction monitoring program.  Can J Hosp Pharm 2004;57(3):183-4

Thistle P, Gottesman M, Pilon R, Glazier RH, Arbess G, Phillips E, Ward RL.  A randomized control trial of an Ultra-Short zidovudine regimen in the prevention of perinatal HIV transmission in rural Zimbabwe.  Cent Afr J Med. 2004 Sep-Oct;50(9-10):79-84.

Knowles SR, Phillips EJ, Wong G, Shear, NH.  Valdecoxib-induced hypersensitivity syndrome: A report of two cases.  J Am Acad Derma 2004;51(6):28-29..

van Heeswijk RPG, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, Cameron DW.  The pharmacokinetics of nelfinavir and M8 during pregnancy and postpartum.  Clin Pharma Ther 2004;76(6):588-97.

Tailor SAN, Simor AE, Cornish W, Phillips E, Knowles S, Rachlis A.  Analysis of spontaneous reports of hypoglycemia and hyperglycemia associated with marketed systemic fluoroquinolones made to the Canadian adverse drug reaction monitoring program.  Can J Hosp Pharm 2004;57(1):12-17. 

Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, Carvalho F, Phillips E, Christiansen FT, Purcell AW, McCluskey J, Mallal S.  Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and ahaplotypic Hsp70-Hom variant.  Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4180-5.

Tang P, Louie M, Richardson SE, Smieja M, Simor AE, Jamieson F, Fearon M, Poutanen SM, Mazzulli T, Tellier R, Mahony J, Loeb M, Petrich A, Chernesky M, McGeer A, Low DE, Phillips E, Jones S, Bastien N, Li Y, Dick D, Grolla A, Fernando L, Henry B,. Rachlis AR, Matukas LM, Rose DB, Lovinsky R, Walmsley S, Gold WL, Krajden S, and the Ontario Laboratory Working Group for the Rapid Diagnosis of Emerging Infections.  Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome:  the Toronto experience. Fast-tracked article. Early release, published at www.cmaj.ca on Dec. 2, 2003. Subject to revision.  CMAJ • JAN. 6, 2004; 170 (1).

Park-Wyllie L, Phillips EJ.  Challenges of adherence management in human immunodeficiency virus pharmacotherapy.  Can J Clin Pharm 2003;10(4):189-195.

Loutfy MR, Raboud JM, Thompson CT, Tseng A, Abdurrahman B, Kovacs CM, Rachlis A, Phillips E, Rubin G, Walmsley S. Clinical impact of double protease inhibitor boosting with amprenavir and lopinavir/ritonavir as part of salvage antiretroviral therapy.  HIV Clin Trials. 2003 Sep-Oct;4(5):301-10.

Phillips EJ, Knowles SR, Shear NH.  Serum-sickness like reaction associated with clopidogrel.  Brit J Clin Pharm. 2003 Nov;56(5):583.

Knowles SR, Phillips EJ, Dresser L, Matukas L.  Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada.  Clin Infect Dis. 2003 Oct 15;37(8):1139-42. Epub 2003 Sep 12.

Phillips EJ, Rachlis AR, Ito S.  Digoxin Toxicity and Ritonavir – A Drug Interaction Mediated Through P-Glycoprotein?  AIDS. 2003 Jul 4;17(10): 1577. 

Phillips EJ, Knowles SR, Shear NH.  Cutaneous manifestations of antiviral therapy.  J Am Acad Dermatol 2003 jun;48(6):985-6. 

Koren G, King S, Knowles S, Phillips E.  Ribavirin in the treatment of SARS: A new trick for an old drug?  CMAJ. 2003 May 13;168(10);1289-92.  (co-author)

Sullivan JD, Phillips EJ, Rachlis A.  Buffalo hump dermatitis: a hat trick of antiretroviral side effects.  Contact Dermatitis. 2003 Mar;48(3):169-170. 

Valois M, Phillips EJ, Shear NH, Knowles SR.  Clindamycin associated acute generalized exanthematous pustulosis.  Contact Dermatitis. 2003 Mar;48(3):169. 

Phillips EIntravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy.  A randomized controlled trial.  Ann Int Med 2001;135:412-22.  ACP Journal Club March/April 2002.

Neuman MG, Malkiewicz IM, Phillips EJ, Rachlis AR, Ong D, Yeung E, Shear NH.  Monitoring Adverse Drug Reactions to Sulfonamide Antibiotics in Human Immunodeficiency Virus-Infected Individuals. Therap Drug Monit. 2002 Dec;24(6):728-736. 

Phillips, EJ, Tseng A.  The chronicles of HIV therapeutics: Where to begin, when to start and how will it end? A tale of two decades and beyond.  Can J Clin Pharm 2002;9(3):120-22.

Phillips EJ, Sullivan JR, Knowles SR, Shear NH.  Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir.  AIDS 2002;16:223-5. (Principal author)

Phillips EJ, Knowles SR, Rachlis AR.  Successful desensitization to efavirenz.  Ann Pharmaco 2002;36(3):430-2.

Phillips EJ, Knowles SR, Weber EA, Blackburn D.  Cephalexin tolerated despite delayed aminopenicillin reactions.  Allergy 2001;56(8):790.

Phillips ECommentary on Freifeld A et al “A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.  N Engl J Med 1999 29;341:305-11 and Kern WV et al Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy N Engl J Med 1999 July 29;341;312-8.  ACP Journal Club 2000;132(2)52-3.

Phillips EJ, Louie M, Knowles SR, Simor AE, Oh, PI.  Cost-effectiveness analysis of six strategies for cardiovascular surgery prophylaxis in patients labeled penicillin allergic.  Am J Health Syst Pharm 2000;57:339-45.

Phillips EJ, Knowles S, Weber E, Shear NH.  Skin reactions associated with bisphosphonates: A report of three cases and an approach to management.  J Allergy and Clin Immun 1998;102:697-8.

Einarson A, Phillips EJ, Mawji F, Alimonte D,D;, Schick B, Addis A. et. al.  A prospective controlled multicentre trial of clarithromycin in pregnancy.  Am J Perinat 1998;15:523-25.

Phillips E, Knowles S, Liu B. Rapid onset of risperidone-induced hepatotoxicity.  Ann Pharm 1998;32:843.

Phillips EJ, Ottaway CA, Freedman J, Kardish M, Li J, Singer W, Fong IW.  The effect of exercise on lymphocyte redistribution and leucocyte function in asymptomatic HIV-infected subjects.  Brain, Behavior and Immunity 1997;11:217-227.

Phillips EJ, Keystone JS, Kain KC.  Failure of combined chloroquine and high dose primaquine treatment for Plasmodium vivax malaria acquired in Guyana, South America.  Clin Infect Dis 1996;23(5):1171-3.

Phillips EJ, Rotstein O.  Transmissible disease risk in trauma to the doctor and patients:  AIDS and hepatitis:  HIV infection risk to the physician.  Annals of the Royal College of Physicians and Surgeons of Canada 1993; 26(2):103-5.

Soskolne CL, Heyland D, Phillips E.  Human T-lymphotropic virus:  exposure and prognosis. CMAJ 1986;134:575-6.